{"id":"NCT00333775","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer","officialTitle":"A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2007-10","completion":"2013-10","firstPosted":"2006-06-06","resultsPosted":"2016-01-27","lastUpdate":"2016-01-27"},"enrollment":736,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Placebo to bevacizumab","otherNames":[]},{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]}],"arms":[{"label":"Docetaxel 100 mg/m^2 plus placebo","type":"EXPERIMENTAL"},{"label":"Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg","type":"EXPERIMENTAL"},{"label":"Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast cancer who are candidates for taxane-based chemotherapy but who have not received prior chemotherapy for metastatic disease. The anticipated time on treatment is 1-2 years and the target sample size is 500+ individuals.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months)","effectByArm":[{"arm":"Docetaxel 100 mg/m^2 Plus Placebo","deltaMin":8,"sd":null},{"arm":"Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg","deltaMin":8.7,"sd":null},{"arm":"Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg","deltaMin":8.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0318"},{"comp":"OG000 vs OG002","p":"0.0036"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":114,"countries":["Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Italy","Lithuania","Mexico","Netherlands","Panama","Poland","Portugal","Romania","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["29522361"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":82,"n":217},"commonTop":["Alopecia","Diarrhoea","Nausea","Nail disorder","Fatigue"]}}